FDA approved Aduhelm earlier this month, despite advisory committee's conclusion that there was not enough evidence to support its effectiveness
FDA approved Aduhelm earlier this month, despite advisory committee's conclusion that there was not enough evidence to support its effectiveness
Lisdexamfetamine found to reduce symptoms of sluggish cognitive tempo in small group of adults with ADHD
Full-time status significantly declined among female physicians with preschool-aged children
At day 15, significantly greater reduction seen in depressive symptoms as measured by change in HAMD-17 score from baseline
At day 15, significantly greater reduction seen in depressive symptoms as measured by change in HAMD-17 score from baseline
Gray market care, from an unregulated agency, often supplements unpaid or family care